Adda Nathalie's Form 4 filing
Enanta Pharmaceuticals Inc (ENTA) · filed Oct 13, 2021
- Accession no.
- 0001177648-21-000027
- Filed
- Oct 13, 2021
- Trade date
- Oct 8-11, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.23M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Adda NathalieCIK 0001646976 | Officer (Sr. VP & Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2021 | Common Stock | MOption exerciseAcquired | +13,453 | $43.46 | +$584,667.38 | 40,397 | Direct | |
| Oct 8, 2021 | Common Stock | SSaleDisposed | −13,453 | $70.09F2 | −$942,920.77 | 26,944 | Direct | |
| Oct 11, 2021 | Common Stock | MOption exerciseAcquired | +4,047 | $43.46 | +$175,882.62 | 30,991 | Direct | |
| Oct 11, 2021 | Common Stock | SSaleDisposed | −4,047 | $70.34F3 | −$284,665.98 | 26,944 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2021 | Common Stock | MOption exerciseDisposed | −13,453 | $0.00 | $0 | 58,817 | Direct | |
| Oct 11, 2021 | Common Stock | MOption exerciseDisposed | −4,047 | $0.00 | $0 | 54,770 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.30, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.05 to $70.85, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 above.